Effects of sildenafil on maximum walking time in patients with arterial claudication The ARTERIOFIL study

Abstract : Background Patients with lower extremity peripheral artery disease (PAD) frequently experience claudication, a clinical symptom indicative of reduced walking capacity. Recommended care consists of exercise rehabilitation combined with optimal medical treatment and surgery. The effects of a single oral dose of sildenafil, a phosphodiesterase type-5 inhibitor, on patients with claudication are discussed. The aim of this study was to test the efficacy of a single 100 mg dose of sildenafil compared to placebo in terms of maximal walking time (MWT) in patients with claudication. Methods The ARTERIOFIL study is a crossover, double-blind, prospective, randomized, single-center study conducted at Angers University Hospital in France. MWT (primary endpoint) was assessed using a treadmill test (10% incline; 3.2 km/h). Secondary endpoints (pain-free walking time (PFWT), transcutaneous oximetry during exercise and redox cycle parameters and safety) were also studied. Results Fourteen patients were included of whom two were ultimately excluded. In the 12 remaining patients, the MWT was significantly improved during the sildenafil period compared with the placebo period (300 s [95% CI 172 s–428 s] vs 402 s [95% CI 274 s–529 s] p < 0.01). Sildenafil had no significant effect on pain-free walking time or skin tissue oxygenation during exercise. According to redox cycle parameters, sildenafil significantly reduced blood glucose and pyruvate levels and the 3-hydroxybutyrate/acetoacetate ratio, while there was no significant effect on lactate, 3-hydroxybutyrate, acetoacetate and free fatty acid levels. Symptomatic transient hypotension was observed in two women. Conclusions The ARTERIOFIL study has shown that a single 100 mg oral dose of sildenafil had a significant effect on increase in MWT but had no significant effects on PFWT and oxygenation parameters in patients with claudication. A double-blind, prospective, randomized, multicenter study (VIRTUOSE©) is ongoing to evaluate the chronic effect of six month-long sildenafil treatment on MWT in PAD patients with claudication. Clinical trial registration This clinical trial was registered at clinicaltrials.gov, registration. number NCT02832570, (https//clinicaltrials.gov/ct2/show/NCT02832570). © 2019 The Authors
Document type :
Journal articles
Complete list of metadatas

Cited literature [49 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02181322
Contributor : Laurent Jonchère <>
Submitted on : Monday, July 15, 2019 - 10:37:52 AM
Last modification on : Wednesday, July 17, 2019 - 1:10:08 PM

File

1-s2.0-S1537189119300801-main ...
Publisher files allowed on an open archive

Identifiers

Citation

Loukman Omarjee, Estelle Le Pabic, Marc-Antoine Custaud, Cédric Fontaine, Clara Locher, et al.. Effects of sildenafil on maximum walking time in patients with arterial claudication The ARTERIOFIL study. Vascular Pharmacology, 2019, 118-119, pp.106563. ⟨10.1016/j.vph.2019.05.003⟩. ⟨hal-02181322⟩

Share

Metrics

Record views

26

Files downloads

33